Efficacy of hepatic arterial infusion chemotherapy and its multimodality therapeutic regimens in treatment of patients with advanced hepatocellular carcinoma and related prognostic factors

Wencong DAI; Mengya ZANG; Guosheng YUAN; Qi LI; Rong LI; Wenli LI; Shuyu DONG; Jinzhang CHEN

doi:10.3969/j.issn.1001-5256.2023.07.013

Volume 39 Issue 7

Jul. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(7): 1592-1599

PDF( 2254 KB)

Efficacy of hepatic arterial infusion chemotherapy and its multimodality therapeutic regimens in treatment of patients with advanced hepatocellular carcinoma and related prognostic factors

DOI: 10.3969/j.issn.1001-5256.2023.07.013

1.
Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangdong Provincial Institute of Liver Diseases, Guangzhou 510515, China
2.
The First Clinical Medical College, Southern Medical University, Guangzhou 510515, China

Research funding:

Natural Science Foundation of Guangdong Province (2022A1515010526);

President Foundation of Nanfang Hospital, Southern Medical University (2018C006)

More Information

Corresponding author: CHEN Jinzhang, chenjinzhang@smu.edu.cn (ORCID: 0000-0003-4964-2218)
Received Date: 2022-11-30
Accepted Date: 2023-01-06
Published Date: 2023-07-20

Abstract

Abstract

Objective To investigate the efficacy of continuous hepatic arterial infusion chemotherapy (HAIC) with the FOLFOX regimen and its multimodality therapeutic regimen in the treatment of patients with advanced hepatocellular carcinoma, as well as the influencing factors for prognosis. Methods A retrospective analysis was performed for the clinical data of 66 patients with advanced hepatocellular carcinoma who received continuous HAIC with FOLFOX regimen in Nanfang Hospital, Southern Medical University, from September 2018 to November 2021. The patients were observed in terms of objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), and median overall survival (mOS) after treatment, and treatment-related adverse reactions were recorded. For the patients with portal vein tumor thrombus, the effect of the treatment on portal vein tumor thrombus was assessed. The Kaplan-Meier method was used for survival analysis, and the Cox regression analysis was used to investigate the influencing factors for prognosis. Results According to the RECIST1.1 criteria, FOLFOX-HAIC and its multimodality therapeutic regimen achieved an ORR of 33.3% (22/66) and a DCR of 86.4% (57/66) in the treatment of 66 patients with advanced hepatocellular carcinoma, with an mPFS time of 8.2 months and an mOS time of 22.1 months. Among the 39 patients with portal vein tumor thrombus, 2 achieved complete remission, 8 achieved partial remission, 24 achieved stable disease, and 5 had disease progression, with an ORR of 25.6% (10/39) and a DCR of 87.2% (34/39). The main adverse reactions included gastrointestinal reactions (16.7%, 11/66), pyrexia (12.1%, 8/66), liver area pain (10.6%, 7/66), bone marrow suppression (3.0%, 2/66), and contrast agent allergy (3.0%, 2/66), and there were no grade > Ⅳ toxic or side effects or deaths caused by such complications. The Cox regression analysis showed that extrahepatic metastasis (hazard ratio [HR]=2.668, 95% confidence interval [CI]: 1.357-5.245, P < 0.05) and prothrombin time (PT) (HR=1.282, 95%CI: 1.080-1.630, P < 0.05) were independent risk factors for PFS, and aspartate aminotransferase level (HR=1.008, 95%CI: 1.002-1.013, P < 0.05) and PT (HR=1.303, 95%CI: 1.046-1.630, P < 0.05) were independent risk factors for OS. Conclusion FOLFOX-HAIC and its multimodality therapeutic regimen has a certain clinical effect with controllable adverse reactions in the treatment of advanced hepatocellular carcinoma.
- Carcinoma, Hepatocellular,
- Molecular Targeted Therapy,
- Prognosis

FullText(HTML)

References(27)

References

[1]	Global Burden of Disease Liver Cancer Collaboration, AKINYEMIJU T, ABERA S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: Results from the global burden of disease study 2015[J]. JAMA Oncol, 2017, 3(12): 1683-1691. DOI: 10.1001/jamaoncol.2017.3055.
[2]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[3]	ZHENG R, ZENG H, ZHANG S, et al. Estimates of cancer incidence and mortality in China, 2013[J]. Chin J Cancer, 2017, 36(1): 66. DOI: 10.1186/s40880-017-0234-3.
[4]	WU T, CHEN L. New advances in the precision diagnosis and treatment of liver cancer[J]. J Clin Hepatol, 2022, 38(3): 497-498. DOI: 10.3969/j.issn.1001-5256.2022.03.001. 吴彤, 陈磊. 肝癌精准诊疗新进展[J]. 临床肝胆病杂志, 2022, 38(3): 497-498. DOI: 10.3969/j.issn.1001-5256.2022.03.001.
[5]	LI Z, ZHU JY. Interpretation of Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(5): 1027-1029. DOI: 10.3969/j.issn.1001-5256.2022.05.010. 李照, 朱继业. 《原发性肝癌诊疗指南(2022年版)》解读[J]. 临床肝胆病杂志, 2022, 38(5): 1027-1029. DOI: 10.3969/j.issn.1001-5256.2022.05.010.
[6]	CHENG AL, KANG YK, CHEN Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo- controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34. DOI: 10.1016/S1470-2045(08)70285-7.
[7]	KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1.
[8]	LYU N, KONG Y, PAN T, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin in hepatocellular cancer with extrahepatic spread[J]. J Vasc Interv Radiol, 2019, 30(3): 349-357. e2. DOI: 10.1016/j.jvir.2018.09.004.
[9]	HE MK, LIANG RB, ZHAO Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2021, 13: 17588359211002720. DOI: 10.1177/17588359211002720.
[10]	KOKUDO N, HASEGAWA K, AKAHANE M, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)[J]. Hepatol Res, 2015, 45(2). DOI: 10.1111/hepr.12464.
[11]	IKEDA M, OKUSAKA T, FURUSE J, et al. A multi-institutional phase Ⅱ trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancer Chemother Pharmacol, 2013, 72(2): 463-470. DOI: 10.1007/s00280-013-2222-x.
[12]	NOUSO K, MIYAHARA K, UCHIDA D, et al. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan[J]. Br J Cancer, 2013, 109(7): 1904-1907. DOI: 10.1038/bjc.2013.542.
[13]	Tumor Interventional Expert Committee of Chinese Anti-Cancer Association. Chinese tumor intervention expert consensus on the application principles of transcatheter arterial infusion chemotherapy[J]. J Intervent Radiol, 2017, 26(11): 963-970. DOI: 10.3969/j.issn.1008-794X.2017.11.001. 中国抗癌协会肿瘤介入专家委员会. 经导管动脉灌注化疗药物应用原则——中国肿瘤介入专家共识[J]. 介入放射学杂志, 2017, 26(11): 963-970. DOI: 10.3969/j.issn.1008-794X.2017.11.001.
[14]	ZHAO M. Hepatic arterial infusion Chemotherapy in the Era of Precise[J]. J Sun Yat-Sen Univ(Medical Sciences), 2019, 40(5): 648-656. DOI: 1672-3554(2019)05-0648-09. 赵明. 精准医疗时代背景下的肝动脉灌注化疗[J]. 中山大学学报(医学科学版), 2019, 40(5): 648-656. DOI: 1672-3554(2019)05-0648-09.
[15]	LI QJ, HE MK, CHEN HW, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: A Randomized Phase Ⅲ Trial[J]. J Clin Oncol, 2022, 40(2): 150-160. DOI: 10.1200/JCO.21.00608.
[16]	SIDAWAY P. FOLFOX-HAIC active in large HCC[J]. Nat Rev Clin Oncol, 2022, 19(1): 5. DOI: 10.1038/s41571-021-00577-y.
[17]	General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009. 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
[18]	Chinese College of Transplant Doctors, Liver Transplantation Group, Chinese Society of Organ Transplantation, Chinese Medical Association. Chinese clinical practice guidelines on liver transplantation for hepatocellular carcinoma (2021edition)[J]. Chin J Dig Surg, 2022, 21(4): 433-443. DOI: 10.3760/cma.j.cn115610-20220316-00135. 中国医师协会器官移植医师分会, 中华医学会器官移植学分会肝移植学组. 中国肝癌肝移植临床实践指南(2021版)[J]. 中华消化外科杂志, 2022, 21(4): 433-443. DOI: 10.3760/cma.j.cn115610-20220316-00135.
[19]	LIU YY. New progress of hepatocellular carcinoma treatment[J]. Chin J Dig Surg, 2022, 21(1): 15-18. DOI: 10.3760/cma.j.cn115610-20220107-00020. 刘允怡. 肝细胞癌治疗的新发展[J]. 中华消化外科杂志, 2022, 21(1): 15-18. DOI: 10.3760/cma.j.cn115610-20220107-00020.
[20]	European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019.
[21]	Liver Cancer Professional Committee of Chinese Anti-Cancer Association. Chinese expert consensus on hepatic arterial infusion chemotherapy for hepatocellular carcinoma (2021 edition)[J]. J Chin J Dig Surg, 2021, 20(7): 754-759. DOI: 10.3760/cma.j.cn115610-20210618-00288. 中国抗癌协会肝癌专业委员会. 肝动脉灌注化疗治疗肝细胞癌中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(7): 754-759. DOI: 10.3760/cma.j.cn115610-20210618-00288.
[22]	HE MK, LE Y, LI QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study[J]. Chin J Cancer, 2017, 36(1): 83. DOI: 10.1186/s40880-017-0251-2.
[23]	HE M, LI Q, ZOU R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: A randomized clinical trial[J]. JAMA Oncol, 2019, 5(7): 953-960. DOI: 10.1001/jamaoncol.2019.0250.
[24]	MEI J, LI SH, LI QJ, et al. Anti-PD-1 immunotherapy improves the efficacy of hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma[J]. J Hepatocell Carcinoma, 2021, 8: 167-176. DOI: 10.2147/JHC.S298538.
[25]	MEI J, TANG YH, WEI W, et al. Hepatic arterial infusion chemotherapy combined With PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma[J]. Front Oncol, 2021, 11: 618206. DOI: 10.3389/fonc.2021.618206.
[26]	WU YB, WU ZQ, HUANG JL, et al. Hepatic arterial infusion chemotherapy for primary liver cancer effect of portal vein tumor thrombus[J]. China Health Standard Management, 2022, 13(12): 109-112. DOI: 10.3969/j.issn.1674-9316.2022.12.027. 吴义波, 吴卓琼, 黄洁丽, 等. 肝动脉灌注化疗对原发性肝癌合并门静脉癌栓的效果[J]. 中国卫生标准管理, 2022, 13(12): 109-112. DOI: 10.3969/j.issn.1674-9316.2022.12.027.
[27]	KE YP, YE SG, LU SB. Short-term efficacy of transcatheter arterial embolization combined with FOLFOX4 regimen of continuous arterial infusion chemotherapy on hepatocellular carcinoma patients with portal vein tumor thrombus[J]. China Med Pharm, 2022, 12(16): 156-159. DOI: 10.3969/j.issn.2095-0616.2022.16.040. 柯映平, 叶绍光, 卢舜彬. 肝动脉栓塞术联合FOLFOX4方案持续动脉灌注化疗对肝细胞癌门静脉癌栓患者的近期疗效[J]. 中国医药科学, 2022, 12(16): 156-159. DOI: 10.3969/j.issn.2095-0616.2022.16.040.

Relative Articles

[1]	Xiuyan LI, Na LEI, Hongfei SONG, Ling ZENG, Dong WANG, Jie MU. The role of endoplasmic reticulum stress in non-alcoholic fatty liver disease and related targeted therapies[J]. Journal of Clinical Hepatology, 2024, 40(11): 2300-2305. doi: 10.12449/JCH241126
[2]	Jing LU, Yamin ZHANG, Hua LI, Yan MIAO. Value of a scoring system based on the serum levels of alpha-fetoprotein and alkaline phosphatase in predicting the prognosis of patients with resectable hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(3): 599-605. doi: 10.3969/j.issn.1001-5256.2023.03.017
[3]	Zhuoran LIU, Jing LI, Yu ZHOU, Pingfu XIONG, Li YANG, Wenguang FU. Value of the nomogram based on HALP score in predicting the prognosis of patients with hepatocellular carcinoma after hepatectomy[J]. Journal of Clinical Hepatology, 2023, 39(7): 1600-1608. doi: 10.3969/j.issn.1001-5256.2023.07.014
[4]	Qiuju PENG, Tao DAI, Guibo XIE, Jinjun CHEN, Xiao CHENG, Yuan YAN. Research advances in transcatheter arterial chemoembolization combined with targeted agents or anti-PD-1/PD-L1 monoclonal antibody in treatment of patients with unresectable hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(7): 1740-1746. doi: 10.3969/j.issn.1001-5256.2023.07.033
[5]	Bailu CAO, Min AI, Ping HUANG, Yongfeng YANG. Research advances in local treatment combined with systemic therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(8): 1972-1976. doi: 10.3969/j.issn.1001-5256.2023.08.031
[6]	Ying TAO, Zhangxiu LIAO. Role of new potential immune blocking molecules in the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(4): 948-955. doi: 10.3969/j.issn.1001-5256.2023.04.031
[7]	Guanqun SUN, Silei ZHOU, Tanlun ZENG, Junyu LIU, Xijun LIANG, Zhuo CHENG. Expression of calcitonin gene-related peptide-receptor component protein in hepatocellular carcinoma and its association with prognosis[J]. Journal of Clinical Hepatology, 2022, 38(6): 1328-1333. doi: 10.3969/j.issn.1001-5256.2022.06.021
[8]	Sirou LI, Yuanlong ZHOU, Keliang LIU, Zhibo LIANG, Jinghua LI. Conversion therapy for massive hepatocellular carcinoma: A case report[J]. Journal of Clinical Hepatology, 2022, 38(7): 1612-1615. doi: 10.3969/j.issn.1001-5256.2022.07.028
[9]	Xiufeng LIU, Jue ZHANG, Lin YAO, Chaoxu YANG. Advances in targeted therapy combined with immunotherapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 992-997. doi: 10.3969/j.issn.1001-5256.2022.05.004
[10]	Mingjun LIU, Yingjuan LIU, Gui YANG, Songmei LIU. Association of the expression of glucose-6-phosphate dehydrogenase with the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1856-1860. doi: 10.3969/j.issn.1001-5256.2021.08.021
[11]	Xiuhong HUANG, Xiaoli XIE, Huiqing JIANG. Value of a microRNA risk score model in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1110-1115. doi: 10.3969/j.issn.1001-5256.2021.05.026
[12]	Weiming YU, Wenqian HONG, Binglun SUN, Jingzhao HAN, Hongfang TUO. Value of albumin-bilirubin grade in predicting liver function changes and prognosis of hepatocellular carcinoma patients undergoing transarterial chemoembolization: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(11): 2575-2583. doi: 10.3969/j.issn.1001-5256.2021.11.018
[13]	Jingzhong OUYANG, Yanzhao ZHOU, Ruili ZHU, Zhengzheng WANG, Xun CHEN, Jinxue ZHOU, Qingjun LI. Application of combined therapy with molecular-targeted drugs and immune checkpoint inhibitors and other combined therapies in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(4): 925-930. doi: 10.3969/j.issn.1001-5256.2021.04.043
[14]	Rui ZHANG, Xiujuan CHANG, Jiamin CHENG, Zhiqin ZHAO, Yinyin LI, Yinying LU, Zhen ZENG. Influence of high-density lipoprotein cholesterol on the prognosis of patients with alcohol-related hepatocellular carcinoma after radical treatment[J]. Journal of Clinical Hepatology, 2021, 37(3): 621-626. doi: 10.3969/j.issn.1001-5256.2021.03.023
[15]	Ningning ZHANG, Wei LU. Targeted therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1753-1757. doi: 10.3969/j.issn.1001-5256.2021.08.003
[16]	Wei JianYing, Sun Wei, Liu XiaoMin, Chen JingLong. Advances in targeted therapy and immunotherapy for hepatocelluar carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(10): 2320-2324. doi: 10.3969/j.issn.1001-5256.2020.10.035
[17]	Niu ChunYan, Zhao XiangYang. Hepatic macrophage-targeted therapy for fatty liver disease: Opportunities and challenges[J]. Journal of Clinical Hepatology, 2020, 36(6): 1393-1397. doi: 10.3969/j.issn.1001-5256.2020.06.045
[18]	DENG HaiMin, DUAN HuaXin. Current status of the research on targeted therapy for cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2020, 36(12): 2856-2859. doi: 10.3969/j.issn.1001-5256.2020.12.046
[19]	Lu Qian, Zhu Li, Cheng Xin, Huang Hua, Chen Zhong. Expression of proteasome subunit beta type 4 in hepatocellular carcinoma and its association with prognosis[J]. Journal of Clinical Hepatology, 2020, 36(2): 372-376. doi: 10.3969/j.issn.1001-5256.2020.02.028
[20]	Huang Shen, Yang ChengLei, Zhang ZhiMing. Research advances in targeted therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(11): 2573-2577. doi: 10.3969/j.issn.1001-5256.2019.11.041

Supplements(0)

Cited By

Cited by

Periodical cited type(5)

1.	康志龙，周益民，宋燕州，张昆，苏一男，魏文平，赵新，李志伟. 靶向免疫治疗联合经肝动脉灌注化疗治疗不可切除肝细胞癌的临床效果及转化治疗的影响因素. 中国医学创新. 2025(01): 47-51 .
2.	许海明，胡永奎，梁平，钟腾猛，陆炳站. 中晚期肝癌患者经动脉化疗栓塞治疗后短期效果及长期预后的影响因素分析. 大医生. 2025(06): 27-31 .
3.	彭林辉，陈涛，徐云修修，王捷，陈捷，李永，黄拼搏，钟国平，陈茜，叶聪婷，陈亚进. mFOLFOX7方案全身化疗联合卡瑞利珠单克隆抗体和阿帕替尼治疗肝细胞癌合并Vp4型门静脉癌栓的疗效. 中华消化外科杂志. 2024(02): 265-271 .
4.	李洁，李瑞娟，鲁志兵，曾筱怡. 肝动脉灌注化疗联合程序性死亡受体1抗体及仑伐替尼治疗晚期肝癌合并门静脉癌栓的效果. 中国当代医药. 2024(26): 43-46+51 .
5.	黄乾鑫，神斌，肖晋昌，高志康，吕墩涛，李艳，徐浩，张庆桥. 载药微球经导管动脉化疗栓塞术联合肠系膜上动脉灌注化疗治疗肝细胞癌合并门静脉癌栓的效果分析. 临床肝胆病杂志. 2024(12): 2457-2463 . 本站查看

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (673) PDF downloads(57)

Efficacy of hepatic arterial infusion chemotherapy and its multimodality therapeutic regimens in treatment of patients with advanced hepatocellular carcinoma and related prognostic factors

DOI: 10.3969/j.issn.1001-5256.2023.07.013